0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
From the Centers for Disease Control and Prevention |

Increased Detections and Severe Neonatal Disease Associated With Coxsackievirus B1 Infection—United States, 2007 FREE

JAMA. 2008;300(1):36-38. doi:10.1001/jama.300.1.36.
Text Size: A A A
Published online

MMWR. 2008;57:553-556

1 figure, 1 table omitted

Enteroviruses generally cause mild disease; however, neonates are at higher risk for severe illness because of the immaturity of their immune systems. Neonatal systemic enterovirus disease, characterized by multiorgan involvement, is among the most serious, potentially fatal conditions associated with enterovirus infection. Typical clinical presentations include encephalomyocarditis (characteristic of group B coxsackieviruses) and hemorrhage-hepatitis syndrome (typical of echovirus 11).1,2 To describe the severity of neonatal illness associated with coxsackievirus B1 (CVB1) infection, CDC analyzed case reports and preliminary data from the National Enterovirus Surveillance System (NESS) for 2007. This report describes the results of that analysis, which indicated that, in 2007, CVB1 for the first time was the predominant enterovirus in the United States, accounting for 113 (25%) of 444 enterovirus infections with known serotypes. In addition, phylogenetic analysis of the 2007 CVB1 strains suggested that the cases resulted from widespread circulation of a single genetic lineage. Health-care providers and public health departments should be vigilant to the possibility of neonatal disease caused by CVB1. Testing for enteroviruses in clinically compatible cases and reporting of identified enteroviruses to NESS should be encouraged.

NESS is a voluntary, passive surveillance system for monitoring enterovirus infections in the United States. Participating laboratories, which include public health and private laboratories and the CDC Picornavirus Laboratory, report enterovirus detections to NESS on a monthly basis. Each report includes age, sex, state, specimen type and collection date, and enterovirus serotype.

Beginning in August 2007, CDC received multiple reports of cases of severe neonatal illness and death associated with enterovirus infection. CVB1 was identified as the causative agent in many of these cases. Previously, no fatal infection of CVB1 had been reported to NESS.3 On the basis of these reports, CDC began a review of clinical, virologic, and surveillance data related to enterovirus for 2007, in collaboration with local and state public health departments and hospitals. A case of CVB1 infection was defined as detection of enterovirus by reverse transcription–polymerase chain reaction (RT-PCR) or viral culture, with the virus typed as CVB1 by molecular (ie, RT-PCR sequencing) or antigenic (ie, neutralization or immunofluorescence) methods.

As of February 1, 2008, NESS had received 514 reports of enterovirus infections in 36 states for 2007. CVB1 was the most commonly detected enterovirus reported to NESS, accounting for 113 (25%) of 444 reports with known serotypes. Other most frequently reported serotypes included echovirus 18 (63 [14%]), echovirus 9 (49 [11%]), and echovirus 6 (37 [8%]). Children aged <1 year accounted for 65 (68%) of 95 CVB1 reports with known age, including 50 (53%) infants aged ≤1 month. CVB1 was detected in 19 states; 58% of all CVB1 detections were reported from California (n = 38) and Illinois (n = 28).

Phylogenetic analysis of current CVB1 strains based on partial sequence of the VP1 gene revealed that all were closely related to each other and to a 2006 strain from Colorado. Analysis also revealed that the strains were more distantly related to earlier strains.

A total of five CVB1-associated neonatal deaths were identified: two from California, one from Illinois, and one death each from Colorado and New Mexico. These came to CDC attention in connection with requests for laboratory assistance. In all five cases, the neonates had multisystem disease with onset within the first 4 days of life. In four of the five fatal cases, the mothers had febrile illness or chorioamnionitis around the time of delivery, suggesting vertical mother-to-infant transmission.

The three distinct clusters of severe enterovirus illness, including illnesses caused by CVB1, detected in Los Angeles, California, Chicago, Illinois, and Kotzebue, Alaska, during 2007 are described below.

Los Angeles County, California. In September 2007, in response to reports of three cases (two of them fatal) of neonatal enterovirus myocarditis, including two in CVB1-positive neonates, the Los Angeles County Department of Public Health asked all hospitals in the county to report all enterovirus-positive cases of severe or fatal myocarditis, aseptic meningitis, or sepsis-like febrile illness that occurred among children during June-November 2007.

A total of 30 enterovirus-positive patients from seven hospitals were identified (all with illness diagnosed by RT-PCR). Median age was 15 days (range: <1 day–14 years); 22 (73%) were aged <1 month. Four (13%) patients aged <1-7 days died, and another 14 (47%) required intensive-care unit (ICU) treatment. Clinical presentations included meningitis (22 patients), myocarditis (12), sepsis-like illness (five), hepatitis (two), coagulopathy (six), and respiratory difficulties (three). Eleven patients, including all nine patients aged <7 days at admission, had illness with multiorgan involvement.

Enterovirus serotype was determined in 19 cases for which isolates obtained by viral culture were available. CVB1 accounted for 14 cases; CVB2 accounted for two cases, and CVB3, CVB4, and echoviruses 7 and 11 accounted for one case each. One patient was coinfected with CVB1 and CVB3. Two of the four patients who died were infected with CVB1. Specimens from the other two patients who died were not available for virus characterization.

CHICAGO, ILLINOIS

In September 2007, the CDC Picornavirus Laboratory identified CVB1 as the source of infection in two cases of severe neonatal disease at Children's Memorial Hospital in Chicago. Subsequently, a review of the hospital's laboratory and medical records was conducted to identify additional enterovirus-positive cases and obtain diagnoses and clinical syndrome information. Fifty enterovirus-positive children (all diagnosed by RT-PCR) were admitted during June 6–November 2, 2007, a 2-fold increase compared with the entire years 2005 (25 patients) and 2006 (26 patients). Median age of patients was 33 days (range: <1 day–8 years); 40 (80%) patients were aged ≤1 month.

Serotype was determined for nine patients admitted to ICU; CVB1 was found in eight patients, and echovirus 18 in one patient. In two other patients, an enterovirus was identified by immunofluorescence staining as a group B coxsackievirus. Specimens from the remaining 39 RT-PCR–positive patients were not available for further virus characterization.

Twelve (24%) infants aged <1-12 days required ICU admission. Their clinical presentations included myocarditis (11 patients), respiratory distress (nine), hepatitis (eight), coagulopathy (six patients), aseptic meningitis (four), and meningoencephalitis (three). Eleven (92%) patients had multiorgan involvement, including five with myocarditis, meningitis, or meningoencephalitis, and hepatitis (three also had coagulopathy). One CVB1-positive patient died, and one required heart transplantation.

KOTZEBUE, ALASKA

In early September 2007, Maniilaq Health Center notified the Alaska Department of Health and Social Services of an increase in severe febrile illness among hospitalized young infants (including three with myocarditis). Medical record review indicated that during August 15–September 11, 2007, seven infants aged ≤1 month (23% of 31 babies born in the Northwest Arctic Borough region since July 1, 2007) had been admitted to the health center with fever and respiratory distress, myocarditis, or meningitis (median age: 18 days; range: 5-48 days). Six patients, five with multiorgan involvement, required ICU treatment, referral to a higher-level hospital, or both. Of these, three patients had myocarditis with aseptic meningitis and respiratory failure (including one with elevated liver enzymes and coagulopathy), two had aseptic meningitis and respiratory distress, and one had aseptic meningitis. The patient with milder illness had a febrile syndrome. None of the patients died.

One patient with myocarditis tested enterovirus-positive by RT-PCR, but the specimen was not available for further virus characterization. CVB1 was isolated from a stool specimen of the patient with aseptic meningitis. The etiologic agent remained unknown in five cases. In addition, CVB1 was isolated from a respiratory specimen of an infant aged 12 months with pneumonia who was treated at the health center as an outpatient during the same period.

REPORTED BY:

L Mascola, MD, D Terashita, MD, Acute Communicable Disease Control, Los Angeles County Dept of Public Health; MB Salzman, MD, Kaiser Permanente West Los Angeles Medical Center; D Schnurr, PhD, S Yagi, T Padilla, Viral and Rickettsial Disease Laboratory, California Dept of Public Health. N Verma, MD, X Zheng, MD, PhD, ST Shulman, MD, Children's Memorial Hospital, Northwestern Univ Feinberg School of Medicine; MU Harris, MSN, Children's Memorial Hospital, Chicago, Illinois. R Gibson, MD, Maniilaq Health Center, Kotzebue; E Funk, MD, Alaska Dept of Health and Social Svcs; T Schmidt, MS, M Westcott, Alaska State Virology Laboratory. C Robinson, PhD, Children's Hospital, Aurora, Colorado. JP Burns, MD, JD, Dept of Pathology, Univ of New Mexico School of Medicine, Albuquerque; Scientific Laboratory Div, New Mexico Dept of Health. N Khetsuriani, MD, PhD, S Oberste, PhD, M Pallansch, PhD, A Fowlkes, MPH, M Wikswo, MPH, Div of Viral Diseases, National Center for Immunization and Respiratory Diseases; Div of Viral and Rickettsial Diseases, National Center for Zoonotic, Vector-Borne and Enteric Diseases; K Sircar, EIS Officer, CDC.

CDC EDITORIAL NOTE:

In 2007, an increased level of CVB1 activity was associated with severe neonatal disease and multiple deaths in the United States. The actual extent of CVB1-associated morbidity and mortality likely was much greater because (1) nonpolio enterovirus infections are not nationally reportable, (2) diagnostic testing for enteroviruses often is not pursued in clinical settings, and (3) serotype identification from enterovirus-positive specimens is not performed routinely. CVB1 has an epidemic pattern of circulation, with increases usually lasting 2-3 years. During 1970-2005, CVB1 accounted for a small (2.3%) but increasing proportion of all enteroviruses reported in the United States.3 In 2007, CVB1 was the most commonly reported serotype, accounting for 25% of all reported enterovirus infections with known serotypes. Until 2007, CVB1 had never been the most commonly reported serotype and, even in peak years, accounted for <10% of all enterovirus reports. The year 2007 also was unusual for the number of CVB1-associated fatalities reported to NESS: 5 fatal cases were reported for the year. CVB1-associated deaths are reported rarely,46 and had not been reported previously to NESS.3,7

Historically, two thirds of CVB1 detections have been among children aged <1 year.3 During 1983-2003, neonates accounted for 22% of CVB1 reports vs 11% for other enteroviruses,7 suggesting a propensity to infect newborns. Cases of neonatal CVB1-associated disease identified in 2007 were characterized not only by myocarditis and central nervous system involvement typical of group B coxsackieviruses but also, on multiple occasions, by hepatitis and coagulopathy, which usually are reported with echovirus 11 infections.

Enterovirus infections are common, particularly during summer-fall months and typically are spread person-to-person via the fecal-oral or oral-oral routes and through respiratory droplets and fomites. Perinatal transmission from mother to infant occurs transplacentally or from exposure to maternal blood or secretions during delivery. Maternal enterovirus illness around the time of delivery and lack of maternal antibodies to an infecting serotype increase the risk for transmission. Onset of enterovirus disease resulting from perinatal transmission occurs in the first 1-2 weeks of life and carries a higher risk for severe illness and death than enterovirus infection acquired during the postnatal period.1,2,8

No treatments approved by the Food and Drug Administration for enterovirus are available. Intravenous immunoglobulin sometimes is used, but its effectiveness in neonatal enterovirus disease is uncertain.2 Use of the candidate antiviral drug pleconaril (Schering-Plough, Kenilworth, New Jersey) showed benefit in neonates with life-threatening enterovirus disease9; a phase 2 clinical trial of pleconaril in neonates is under way.10

In the absence of vaccines, nonpolio enterovirus transmission can be reduced by adherence to good hygienic practices, such as thorough hand-washing (especially after diaper changes), disinfection of contaminated surfaces by chlorine-containing household cleaners, and avoidance of shared utensils and drinking containers. To prevent nosocomial transmission of enteroviruses, neonatal hospital units should strictly enforce routine infection-control measures.

Serotype identification is important for recognizing differences in clinical profiles and outcomes between enteroviruses during seasonal outbreaks.2 Enterovirus RT-PCR testing allows rapid and sensitive detection of enteroviruses in clinical samples but does not differentiate serotypes. Molecular typing of enteroviruses based on VP1 gene sequence, which permits rapid identification of any enterovirus and provides data for phylogenetic analysis, is increasingly available at public health laboratories.2 Because serotype-specific surveillance for enteroviruses is helpful for monitoring trends in enterovirus circulation and identification of the emergence of new predominant serotypes or strains, public health agencies and private laboratories should report enterovirus detections to NESS.

REFERENCES

Modlin JF. Perinatal echovirus infection: insights from a literature review of 61 cases of serious infection and 16 outbreaks in nurseries.  Rev Infect Dis. 1986;8(6):918-926
PubMed   |  Link to Article
Abzug MJ. Presentation, diagnosis, and management of enterovirus infections in neonates.  Paediatr Drugs. 2004;6(1):1-10
PubMed   |  Link to Article
Khetsuriani N, Lamonte-Fowlkes A, Oberst S, Pallansch MA.Centers for Disease Control and Prevention.  Enterovirus surveillance—United States, 1970-2005.  MMWR Surveill Summ. 2006;55(8):1-20
PubMed
Chiou CC, Liu WT, Chen SJ,  et al.  Coxsackievirus B1 infection in infants less than 2 months of age.  Am J Perinatol. 1998;15(3):155-159
PubMed   |  Link to Article
Wright HT, Okuyama K, McAllister RM. An infant fatality associated with coxsackie B1 virus.  J Pediatr. 1963;63:428-431
PubMed   |  Link to Article
Lau G. Acute fulminant, fatal coxsackie B virus infections: a report of two cases.  Ann Acad Med Singapore. 1994;23(6):917-920
PubMed
Khetsuriani N, LaMonte A, Oberste MS, Pallansch M. Neonatal enterovirus infections reported to the national enterovirus surveillance system in the United States, 1983-2003.  Pediatr Infect Dis J. 2006;25(10):889-893
PubMed   |  Link to Article
Lin TY, Kao HT, Hsieh SH,  et al.  Neonatal enterovirus infections: emphasis on risk factors of severe and fatal infections.  Pediatr Infect Dis J. 2003;22(10):889-894
PubMed   |  Link to Article
Rotbart HA, Webster AD.Pleconaril Treatment Registry Group.  Treatment of potentially life-threatening enterovirus infections with pleconaril.  Clin Infect Dis. 2001;32(2):228-235
PubMed   |  Link to Article
Collaborative Antiviral Study Group.  Clinical trials. Pleconaril enteroviral sepsis syndrome. Protocol CASG 106 (DMID#99-018). http://www.casg.uab.edu/new%20clinical%20trials%20page.htm

Figures

Tables

References

Modlin JF. Perinatal echovirus infection: insights from a literature review of 61 cases of serious infection and 16 outbreaks in nurseries.  Rev Infect Dis. 1986;8(6):918-926
PubMed   |  Link to Article
Abzug MJ. Presentation, diagnosis, and management of enterovirus infections in neonates.  Paediatr Drugs. 2004;6(1):1-10
PubMed   |  Link to Article
Khetsuriani N, Lamonte-Fowlkes A, Oberst S, Pallansch MA.Centers for Disease Control and Prevention.  Enterovirus surveillance—United States, 1970-2005.  MMWR Surveill Summ. 2006;55(8):1-20
PubMed
Chiou CC, Liu WT, Chen SJ,  et al.  Coxsackievirus B1 infection in infants less than 2 months of age.  Am J Perinatol. 1998;15(3):155-159
PubMed   |  Link to Article
Wright HT, Okuyama K, McAllister RM. An infant fatality associated with coxsackie B1 virus.  J Pediatr. 1963;63:428-431
PubMed   |  Link to Article
Lau G. Acute fulminant, fatal coxsackie B virus infections: a report of two cases.  Ann Acad Med Singapore. 1994;23(6):917-920
PubMed
Khetsuriani N, LaMonte A, Oberste MS, Pallansch M. Neonatal enterovirus infections reported to the national enterovirus surveillance system in the United States, 1983-2003.  Pediatr Infect Dis J. 2006;25(10):889-893
PubMed   |  Link to Article
Lin TY, Kao HT, Hsieh SH,  et al.  Neonatal enterovirus infections: emphasis on risk factors of severe and fatal infections.  Pediatr Infect Dis J. 2003;22(10):889-894
PubMed   |  Link to Article
Rotbart HA, Webster AD.Pleconaril Treatment Registry Group.  Treatment of potentially life-threatening enterovirus infections with pleconaril.  Clin Infect Dis. 2001;32(2):228-235
PubMed   |  Link to Article
Collaborative Antiviral Study Group.  Clinical trials. Pleconaril enteroviral sepsis syndrome. Protocol CASG 106 (DMID#99-018). http://www.casg.uab.edu/new%20clinical%20trials%20page.htm
CME
Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Collections
PubMed Articles